Press release
Immune-Mediated Inflammatory Diseases Market Top Companies Study - Novartis AG (Switzerland), Daiichi Sankyo Company, Limited (Japan), Pfizer Inc. (U.S.)
Immune-Mediated Inflammatory Diseases Market
According to the latest research by InsightAce Analytic, the Immune-Mediated Inflammatory Diseases Market is predicted to grow with a CAGR of 7.10% during the forecast period of 2024-2031.
Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2889
Immune-mediated inflammatory diseases (IMIDs) comprise a group of interrelated disorders characterized by common inflammatory mechanisms driven by immune system dysregulation, although their precise etiology remains unclear. These conditions arise from an overactive or improperly functioning immune response and are associated with heightened risks of morbidity, mortality, and long-term organ damage.
The global prevalence of autoimmune disorders has been increasing steadily, driven by a combination of genetic susceptibility and modifiable lifestyle factors such as sedentary behavior and suboptimal dietary habits. This rising incidence is fueling growth in the global IMID therapeutics market, as there is an expanding need for effective treatment options and innovative therapeutic solutions to manage these complex, chronic conditions.
List of Prominent Players in the Immune-Mediated Inflammatory Diseases Market:
• Novartis AG
• Daiichi Sankyo Company, Limited
• Pfizer Inc.
• Abbvie Inc.
• Merck & Co Inc.
• Zydus Group
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceuticals Industries Ltd.
• Amgen Inc.
• Boehringer Ingelheim International GmbH.
• AstraZeneca
• Ampio Pharmaceuticals Inc.
• Eli Lilly
• Akorn Incorporated
Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04
Market Dynamics
Growth Drivers:
The global market for immune-mediated inflammatory diseases (IMIDs) is expected to achieve sustained growth, primarily driven by the rising prevalence of chronic conditions such as psoriasis, Crohn's disease, and rheumatoid arthritis. Expansion is further supported by the increasing adoption of advanced biologic therapies that provide targeted treatment options. In addition, enhanced patient access through diverse distribution channels-including specialty clinics, retail pharmacies, and digital health platforms-is contributing to market momentum.
Challenges:
Despite promising growth prospects, the market faces notable challenges. A shortage of healthcare professionals skilled in administering complex biologic therapies can limit treatment accessibility. Furthermore, adverse effects associated with certain treatments-such as dermatological reactions and complications from immunosuppressive drugs-may affect patient adherence and clinical outcomes. The COVID-19 pandemic also disrupted market activity, as healthcare systems deferred non-urgent procedures and redirected resources to pandemic response efforts, resulting in temporary declines in market performance.
Regional Insights:
North America is projected to maintain its leadership position in the global IMID market in terms of revenue, supported by a high prevalence of autoimmune disorders, growing demand for biologic therapeutics, and robust research and development initiatives targeting novel treatments. The approval and commercialization of innovative therapies, alongside increased utilization of immunosuppressive agents, continue to drive regional growth.
Meanwhile, the Asia-Pacific region is experiencing accelerated expansion, fueled by greater awareness of autoimmune diseases, ongoing improvements in healthcare infrastructure, and advances in diagnostic and treatment technologies for inflammatory conditions.
Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2889
Recent Developments:
• In July 2024, AbbVie announced that the European Commission has sanctioned SKYRIZI® (risankizumab) for the treatment of elderly individuals with moderately to severely active ulcerative colitis (UC) who have experienced an inadequate response to, lost response to, or exhibited intolerance to conventional or biologic therapies.
Segmentation of Immune-Mediated Inflammatory Diseases Market-
By Indication-
• Asthma,
• Chronic Obstructive Pulmonary Diseases (COPD)
• Inflammatory Bowel Disease (IBD)
• Systemic Lupus Erythematosus (SLE)
• Rheumatoid Arthritis (RA)
• Psoriasis
• Others
By Treatment Type-
• Traditional Drugs
• Biologic Therapies
• Novel Therapies
By Route of Administration-
• Oral
• Parenteral
• Others
By End-Users-
• Hospitals
• Specialty Clinics
• Others
By Distribution Channel-
• Hospital Pharmacy
• Retail Pharmacy
• Others
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa
Read Overview Report- https://www.insightaceanalytic.com/report/immune-mediated-inflammatory-diseases-market/2889
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.
Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Immune-Mediated Inflammatory Diseases Market Top Companies Study - Novartis AG (Switzerland), Daiichi Sankyo Company, Limited (Japan), Pfizer Inc. (U.S.) here
News-ID: 4171374 • Views: …
More Releases from Insightace Analytic Pvt Ltd.
Transthyretin Amyloidosis Treatment Market Top Players - American Express, Bank …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Transthyretin Amyloidosis Treatment Market - (By Type (ATTR-PN, ATTR-CM), By Therapy (Targeted Therapy (Onpattro, Inotersen, Vyndaqel/Vyndamax), Supportive Therapy, Pipeline Therapy), By Disease Type (Hereditary Transthyretin Amyloidosis (Polyneuropathy, Cardiomyopathy, Mixed Type), Wild Type Amyloidosis), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the…
Alopecia Market Key Players Analysis - Pfizer, Inc., Lilly, Lexington Intl., LLC …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Alopecia Market - (By Disease Type (Alopecia Areata, Cicatricial Alopecia, Traction Alopecia, Androgenetic Alopecia, Alopecia Totalis, Alopecia Universalis), By Treatment (Pharmaceutical, Devices), By Gender (Male, Female), By Sales Channel (Prescriptions, OTC), By End-use), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Alopecia Market is valued at…
Autosomal Dominant Hypocalcemia Type 1 Market Outlook Covering Treatment Adoptio …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Autosomal Dominant Hypocalcemia Type 1 Market - (By Treatment (Calcium Analogs, Vitamin Analogs), By End-User (Hospitals, Clinics, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Autosomal Dominant Hypocalcemia Type 1 Market is predicted to grow with a CAGR of 2.96% during the forecast period of…
Diabetic Macular Edema Market Growth Drivers Treatment Advancements and Regional …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Diabetic Macular Edema Market - (By Drug Type (Anti-VEGF (Ranibizumab (Lucentis), Aflibercept (Eylea)), Corticosteroid Therapies (Dexamethasone (Ozurdex), Fluocinolone Acetonide (Iluvien)), Others), By Form (Intravitreal Injections, Intravitreal Implants), By Distribution Channel (Hospitals, Specialty Clinics, Mail Order Pharmacies)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Diabetic Macular…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
